Tip 1 Diabetes Mellitus Tanılı Hastalarda Poliglandüler Otoimmün Sendrom Sıklığının Tespiti ve Diyabetin Prognoz ve Komplikasyonları ile İlişkisinin Araştırılması
Amaç: Tip 1 diabetes mellitus (T1DM) tanılı hastaların üçte birinde otoimmün poliglandüler sendrom (OPS) bulunmaktadır. Çalışmada
T1DM’ye eşlik eden OPS sıklığı ve diyabetin prognoz, komplikasyonları ile ilişkisinin araştırılması amaçlanmıştır.
Gereç ve Yöntemler: Çalışmaya Endokrinoloji polikliniğine başvuran ve T1DM tanısı ile takipli 99 hasta dahil edildi. Verilerin analizinde
Ki-Kare analizi (Pearson Chi-kare), Kolmogorov-Smirnov testi, Student t-testi, Mann Whitney-U testi, Spearman Korelasyon testi ve
Kruskal Wallis testi kulanılmıştır. Verilerin analizinde SPSS 22 paket programı kullanıldı. Anlamlılık değeri p≤ 0,05 olarak alındı.
Bulgular: Çalışmaya alınan hastaların 25’inde (%25,3) hipotiroidi ve 8’inde (%8,1) çölyak hastalığı saptandı. Hastaların 9’unda (%9,1)
anti endomisyum antikor, 50’sinde (%50,5) adacık antikoru, 22’sinde (%22,2) anti insülin antikor, 26’sında (%26,3) anti parietal antikor,
8’inde (%8,1) doku transglutaminaz IG A, 43’ünde (%43,4) ANA, 4’ünde (%4,0) ASMA pozitifliği ve 25’inde (%25,3) OPS varlığı tespit
edildi. T1DM tanılı hastalarda retinopati, nöropati ve nefropati gelişen hastaların hastalık süresi gelişmeyenlerin hastalık süresinden
anlamlı şekilde yüksek olduğu tespit edildi. Hastaların hastalık yılı ile VKİ ve bel çevresi arasında pozitif yönde, hastalık yılı ile HbA1c
ve c peptit arasında ise negatif yönde anlamlı bir korelasyon saptandı. OPS varlığı arasında retinopati varlığı, nöropati varlığı ve nefropati
varlığı açısından anlamlı farklılık olmadığı saptandı. Bunun yanında OPS varlığı arasında HbA1c değeri açısından da anlamlı farklılık
görülmedi.
Sonuç: T1DM tanılı hastalarda diğer otoimmün hastalıkların sıklığında yıllar geçtikçe ciddi bir artış gelişmekte olup, diyabetik hastaların
takiplerinde komplikasyon risklerinin azaltılması, iyi bir prognoz, iyi klinik gelişim ve erken tanı açısından otoimmün hastalıkların
diyabetin hem tanı anında hem de ilerleyen yıllarında dikkate alınması gerekmektedir
Investigation of the Frequency of Polyglandular Autoimmune Syndrome in Patients with Type 1 Diabetes Mellitus and Its Relationship with the Prognosis and Complications of Diabetes
Aim: One third of patients with type 1 diabetes mellitus (T1DM) have an autoimmune polyglandular syndrome (OPS). In this study, it
was aimed to investigate the frequency of OPS accompanying T1DM and the relationship of diabetes with prognosis and complications.
Material and Methods: Our study included 99 patients who applied to the endocrine outpatient clinic and were followed up with
the diagnosis of T1DM. Chi-square analysis (Pearson Chi-square), Kolmogorov-Smirnov test, Student’s t-test, Mann Whitney-U test,
Spearman Correlation test and Kruskal Wallis test were used in the analysis of the data. SPSS 22 package program was used in the
analysis of the data. The significance value was taken as p≤ 0.05.
Results: Of the patients included in the study, 25 (25.3%) had hypothyroidism and 8 (8.1%) had celiac disease. Anti-endomysium
antibodies in 9 (9.1%), islet antibodies in 50 (50.5%), anti-insulin antibodies in 22 (22.2%) patients, and anti-parietal antibodies in 26
(26.3%) patients’ antibody, tissue transglutaminase IG A in 8 (8.1%), ANA in 43 (43.4%), ASMA positivity in 4 (4.0%) and OPS in 25
(25.3%) detected. It was determined that the duration of the disease of the patients with retinopathy, neuropathy and nephropathy in
T1DM patients was significantly higher than the duration of the disease in those who did not. It was found that there was a positive
correlation between the patients’ disease year and BMI and waist circumference, and a negative correlation between the disease year and
HbA1c and C peptide. It was determined that there was no significant difference between the presence of OPS in terms of presence of
retinopathy, presence of neuropathy) and presence of nephropathy. In addition, there was no significant difference between the presence
of OPS in terms of HbA1c value.
Conclusion: The incidence of other autoimmune diseases has increased significantly over the years in patients with T1DM, and
autoimmune diseases should be considered both at the time of diagnosis and in the following years in terms of reducing the risk of
complications in the follow-up of diabetic patients, a good prognosis, good clinical development and early diagnosis.
___
- 1. Alemzadeh R, Ali O. Diabetes Mellitus. In: Behrman RE,
Kliegman RM, Jenson HB, et al. Nelson Textbook of Pediatrics.
19 th ed. Philadelphia: Elsevier Saunders, 2011: 1968-1990.
- 2. Saka N, Baş F. Diabetes Mellitus. Neyzi O, Ertuğrul T, editörler.
Pediyatri’de. İstanbul: Nobel Matbaacılık, 2010; 1625-1641.
- 3. Winter WE. The use of islet autoantibody markers in the
prediction of autoimmune type 1 diabetes. Clin Immunol
Newslett 1999; 19: 25-39.
- 4. Bach JF. Infections and autoimmune diseases. J Autoimmun
2005; 25: 74-80.
- 5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M.
Immunologic self-tolerance maintained by activated T cells
expressing IL-2 receptor a-chains (CD25). Breakdown of a
singlemechanism of self-tolerance causes various autoimmune
diseases. J Immunol 1995; 155: 1151-1164.
- 6. Neufeld M, Maclaren N, Blizzard R. Autoimmune
polyglandular syndromes. Pediatr Ann 1980; 9: 154-162.
- 7. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives
on disease pathogenesis and treatment. Lancet 2001; 358: 221-
229
- 8. Tuomilehto J. The emerging global epidemic of type 1 diabetes.
Curr Diab Rep 2013; 13: 795-804.
- 9. Hansen MP, Kahaly GJ. Autoimmune polyglandularsyndromes.
Dtsch Med Wochenschr 2013; 138: 319-326.
- 10. Chong V, Leong K, Wallymahmed M, Sturgess R, MacFarlane
A. Is coeliac disease more prevalent in young adults with
coexisting type 1 diabetes mellitus and autoimmune thyroid
disease compared with those with type 1 diabetes mellitus
alone? Diabet Med 2002; 19: 334-337.
- 11. Evertsen J, Alemzadeh R, Xujing W. Incidence of pediatric type
1 diabetes mellitus in Southeastern Wisconsin: Relationship
with body weight at diagnosis. Plos One 2009; 4: 873-877.
- 12. Taşkın E, Yılmaz E, Kılıç M, Ertuğrul S. İnsüline bağımlı
diabetes mellitusun epidemiyolojik özellikleri. FÜ Sağ Bil
Dergisi 2007; 21: 75-79.
- 13. Şimşek E, Karabay M, Kocabay K. Batı Karadeniz Bölgesinde
yaşayan çocuklarda insüline bağımlı diabetes mellitusun
epidemiyolojik özellikleri. Türk Pediatri Arşivi 2003; 38: 216-
222.
- 14. Kandemir N, Açikgöz E, Yordam N. The epidemiology of
juvenile-onset insulin-dependent diabetes mellitus in Turkish
children. A retrospective analysis of 477 cases. Turk J Pediatr
1994; 36: 191-195.
- 15. Diabetes Control and Complication Trial Research Group, The
Effect of Intensive Treatment pof Diabetes on the developement
and progression of Long-Term Complications in Insulin-
Diependet Diabetes Mellitus. New Eng J of Medicine 329: 977-
986
- 16. Mortensen HB, Hougaard P (1997) Comparison of
metaboliccontrol in a cross-sectional study of 2,873 children
and adolescents with IDDM from 18 countries. The Hvidore
study group on childhood diabetes. Diabetes Care 20: 714-720
- 17. Daneman D, Wolfson DH, Becker DJ, Drash AL. Factors
affecting glycosylated hemoglobin values in children with
insulin-dependent diabetes. J Pediatr 1981; 99: 847-853.
- 18. Kaufman FR, Halvorson M, Carpenter S. Association between
diabetes control and visits to a multidisciplinary pediatric
diabetes clinic. Pediatrics 1999; 103: 948-951.
- 19. Gerstl EM, Rabl W, Rosenbauer J, Gröbe H, Hofer SE, Krause U,
Holl RW. Metabolic control as reflected by HbA1c in children,
adolescents and young adults with type-1 diabetes mellitus:
combined longitudinal analysis including 27,035 patients from
207 centers in Germany and Austria during the last decade.
Eur J Pediatr 2008; 167: 447-453.
- 20. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio
LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR,
Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum
CJ; T1D Exchange Clinic Network. Prevalence of detectable
C-Peptide according to age at diagnosis and duration of type 1
diabetes. Diabetes Care 2015; 38(3): 476-481.
- 21. Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson
J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren
B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK,
Wareham N, Leslie RD, Pozzilli P. Age-dependent decline of
β-cell function in type 1 diabetes after diagnosis: a multi-centre
longitudinal study. Diabetes Obes Metab 2014; 16: 262-267.
- 22. Olsen BS, Johannesen J, Sjølie AK, Borch-Johnsen K,
Hougarrdss P, Thorsteinsson B. Metabolic control and
prevalence of microvascular complications in young Danish
patients with Type 1 diabetes mellitus. Diabet Med 1999; 16:
79-85.
- 23. Salgado PP, Silva IN, Vieira EC, Simões e Silva AC J Pediatr
Endocrinol Metab 2010; 23: 1311-1320.
- 24. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch
P. Diabetic nephropathy in 27,805 children, adolescents, and
adults with type 1 diabetes: effect of diabetes duration, A1C,
hypertension, dyslipidemia, diabetes onset, and sex. Diabetes
Care 2007; 30: 2523-2528.
- 25. Kong YH, Kim MS, Lee DY. Comparison of the prevalance
of islet autoantibodies according to age disease duration in
patients with type 1 diabetes mellitus. Ann Pediatr Endocrinol
Metab 2013; 18: 65-70.
- 26. Demir F, Günöz H, Saka N, Darendeliler F, Bundak R, Baş F,
Neyzi O. Epidemiologic features of type 1 diabetic patients
between 0 and 18 years of age in Istanbul City. J Clin Res
Pediatr Endocrinol 2015; 7: 49-56.
- 27. Kocabaş A, Aldemir Kocabaş B, Karagüzel G, Akçurin S. Tip
1 diabetes mellitus olgularımızın antropometrik ve metabolik
izlem özelliklerinin değerlendirilmesi. Türkiye Çocuk
Hastalıkları Dergisi 2013; 3: 113-118.
- 28. Lee, K. Factors associated with the development of anti-insulin
antibody in diabetic children. J Korean Soc Pediat Endocrinol
2000, 5: 100-106.
- 29. Kordonouri O, Klinghammer A, Lang EB, Gruters-Keslich A,
Grabert M, Holl RW. Thyroid autoimmunity in children and
adolescents with type 1 diabetes. Diabetes Care 2002; 25: 1346-
1350.
- 30. Kim EY, Shin CH, Yang SW. Polymorphisms of HLA class II
predispose children and adolescents with type 1 diabetes to
autoimmune thyroid disease. Autoimmunity 2003; 36: 177-
181.
- 31. Rattarasarn C, Diosdado MA, Ortego J, Leelawattana
R, Soonthornpun S, Setasuban W, Jaruratanasirikul S,
Patarakijvanich N. Thyroid autoantibodies in Thai type 1
diabetic patients: clinical significance and their relationship
with glutamic acid decarboxylase antibodies. Diabetes Res
Clin Pract 2000; 49: 107-111.
- 32. Sara Derrou, Fayçal El Guendouz, Yousra Benabdelfedil,
Imad Chakri, Hassan Ouleghzal, Somaya Safi. The profile of
autoimmunity in Type 1 diabetes patients. Ann Afr Med 2021;
20: 19-23.
- 33. Kawasaki E. Type 1 diabetes and autoimmunity, department
of diabetes and metabolisme, Nagasaki harbor medical center
city hospital, Nagasaki Japon. Clin Pediate Endocrinol 2014;
23: 99-105.
- 34. Kahaly GJ, Hansen MP. Type 1 diabetes associated
autoimmunity. Autoimmun Rev 2016; 15: 644-648.
- 35. Porandalaa S, Chitturia S, Sethia BK. Autoimmune thyroid
disease in type 1 diabetes mellitus. Diabetes Res Clin Pract
2000; 50: 97-101.
- 36. Sharifi F, Ghasemi L, Mousavinasab N. Thyroid function and
anti-thyroid antibodies in Iranian patients with type 1 diabetes
mellitus: influences of age and sex. Iran J Allergy Immunol
2008; 7: 31-6.
- 37. Castaner M, Molina A, Jimenez-Lopez L, Gomez J, Soler J.
Clinical presentation and early course of type 1 diabetes in
patients with and without thyroid autoimmunity. Diabetes
Care 1999; 22: 377-81.
- 38. Ardestani S, Keshteli A, Khalili N, Hashemipour M, Barekatain
R. Thyroid disorders in children and adolescents with type 1
diabetes mellitus in Isfahan, Iran. Iran J Pediatr 2011; 21: 502-
508.
- 39. Prinz N, Tittel SR, Bachran R, Birnbacher R, Brückel J,
Dunstheimer D, Haberland H, Hess M, Karges W, Oeverink
R, Veigel A, Holl RW. Characteristics of Patients with
Type 1 Diabetes and Additional Autoimmune Disease
in the DPV Registry. J Clin Endocrinol Metab. 2021 Aug
18;106(9):e3381-e3389.
- 40. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenberg
E, Nelson JC, Gottlieb PA, Rewers M, Eisenbarth GS.
Autoantibody “subspecificity” in type 1 diabetes: risk for
organ-specific autoimmunity clusters in distinct groups.
Diabetes Care 2005; 28: 850-855.
- 41. Peretti N, Bienvenu F, Bouvet C, Fabien N, Tixier F, Thivolet
C, Levy E, Chatelain PG, Lachaux A, Nicolino M. The
temporal relationship betweenthe onset of type 1 diabetes
and celiac disease: a study based on immunoglobulin A
antitransglutaminase screening. Pediatrics 2004; 113: 418-422.
- 42. Karavanaki K, Kakleas K, Paschali E, Kefalas N, Konstantopoulos
I, Petrou V, Kanariou M, Karayianni C. Screening for associated
autoimmunity inchildren and adolescents with type 1 diabetes
mellitus (T1DM). Horm Res 2009; 71: 201-206.
- 43. Djurić Z, Stamenković H, Stanković T, Milićević R, Branković
L, Cirić V, Katić V. Celiac disease prevalence in children and
adolescents with type1 diabetes from Serbia. Pediatr Int 2010;
52: 579-583.
- 44. Bhadada SK, Kochhar R, Bhansali A, Dutta U, Kumar PR,
Poornachandra KS, Vaiphei K, Nain CK, Singh K. Prevalence
and clinical profile of celiac disease in type 1 diabetes mellitus
in north India. J Gastroenterol Hepatol 2011; 2: 378-381.
- 45. Gabriel S, Mihaela I, Angela B, Mariana A, Doru D. Prevalence
of IgAantitissue transglutaminase antibodies in children with
type 1 diabetesmellitus. J Clin Lab Anal 2011; 25: 156-161.
- 46. Rami B, Sumnik Z, Schober E, Waldhör T, Battelino T, Bratanic
N, Kürti K, Lebl J, Limbert C, Madacsy L, Odink RJ, Paskova
M, Soltesz G. Screening detected celiac disease in children with
type 1 diabetes mellitus: effect on the clinical course (a case
control study). J Pediatr Gastroenterol Nutr 2005; 41(3): 317-
321.
- 47. Picarelli A, Di Tola M, Sabbatella L, Mercuri V, Pietrobono
D, Bassotti G, D’Amico T, Donato G, Picarelli G, Marino M,
Borghini R, Centanni M, Gargiulo P. Type 1 diabetes mellitus
and celiac disease: endothelial dysfunction. Acta Diabetol
2013; 50(4): 497-503.
- 48. Bakker SF, Tushuizen ME, von Blomberg ME, Mulder CJ,
Simsek S. Type 1 diabetes and celiac disease in adults: glycemic
control and diabetic complications. Acta Diabetol. 2013; 50:
319-324.
- 49. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger
DB. A longitudinal study of the effects of a gluten-free diet
on glycemic control and weight gain in subjects with type 1
diabetes and celiac disease. Diabetes Care 2002; 25: 1117-1122.
- 50. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Clinical
profile of coexisting conditions in type 1 diabetes mellitus
patients. Diabetes Metab Syndr 2012; 6: 70-76.
- 51. Kaspers S, Kordonouri O, Schober E. Anthropometric
parameters, metabolic control and thyroid autoimmunity
in 127 biopsy-positive children and adolescents with Type 1
diabetes and celiac disease compared to 18,470 diabetic subjects
without celiac disease. A multicenter survey. Diabetologia
2003; 44: 232-233.
- 52. Strickland RG, Mackay I. A reappraisal of the nature and
significance of chronic atrophic gastritis. Am J Dig Dis 1973;
18: 426-440.
- 53. Magzoub MM, Abdel-Hameed AA, Bottazzo GF. Prevalence of
islet cell and thyrogastric autoantibodies in Sudanese patients
with type 1 diabetes. Diabet Med 1994; 11: 188-192.
- 54. akleas K, Kostaki M, Critselis E, Karayianni C, Giannaki
M, Anyfantakis K, Haramaras I, Fotinou A, Papathanasiou
A, Karavanaki K. Gastric Autoimmunity in Children and
Adolescents with Type 1 Diabetes: A Prospective Study. Horm
Res Paediatr 2012; 77: 121-126.
- 55. Muhsen K, Barak M, Henig C, Alpert G, Ornoy A, Cohen D.
Is the association between Helicobacter pylori infection and
anemia age dependent? Helicobacter 2010; 15: 467-472.
- 56. Barker JM: Clinical review: type 1 diabetes associated
autoimmunity: natural history, genetic association, and
screening. J Clin Endocrinol Metab 2006; 9: 1210-1217.
- 57. Maggiore G, Bernard O, Homberg JC, Hadchouel M, Alvarez
F, Hadchouel P, Odièvre M, Alagille D: Liver disease associated
with anti-liver kidney microsome antibody in children. J
Pediatr 1986; 108: 399-404.
- 58. Allen S, Huber J, Devendrac D: Prevalence of organ-specific
autoantibodies in childhood- and adult-onset type 1 diabetes.
Ann N Y Acad Sci 2008; 1150: 260-262.
- 59. Heras P, Mantzioros M, Mendrinos D, Heras V, Hatzopoulos
A, Xourafas V, Kritikos K, Karagiannis S. Autoantibodies in
type 1 diabetes. Diabetes Res Clin Pract 2010; 90: 40-42.
- 60. Al-Hussaını, Abdulrahman A. Autoimmune hepatitis related
autoantibodies in children with type 1 diabetes. Diabetology &
Metabolic Syndrome 2014; 6: 1-5.
- 61. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J
Endocrinol 2009; 161: 11-20.
- 62. Kakleas K, Soldatou A, Karachaliou F, Karavanaki K. Associated
autoimmune diseases in children and adolescents with type 1
diabetes mellitus (T1DM). Autoimmun Rev 2015; 14: 781-797.
- 63. Förster G, Krummenauer F, Kühn I, Beyer J, Kahaly G.
Polyglandular autoimmune syndrome type II: epidemiologyand
forms of manifestation. Dtsch Med Wochenschr 1999; 124:
1476-1481.
- 64. Ben-Skowronek I, Michalczyk A, Piekarski R, WysockaŁukasik
B, Banecka B. Type III Polyglandular Autoimmune
Syndromes in children with type 1 diabetes mellitus. Ann
Agric Environ Med 2013; 20: 140-146.
- 65. Prinz N, Tittel SR, Bachran R, Birnbacher R, Brückel J,
Dunstheimer D, Haberland H, Hess M, Karges W, Oeverink
R, Veigel A, Holl RW. Characteristics of Patients with Type
1 Diabetes and Additional utoimmune Disease in the DPV
Registry. J Clin Endocrinol Metab 2021;10.